Endocrine tumors of the pancreas: Classification, clinical and molecular prognostic factors;Classification et facteurs pronostiques morphologiques et moléculaires des tumeurs endocrines du pancréas

Annales de Pathologie

Volumn 22, Issue 5, 2002, Pages 367-374

  Terris, Benoît ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

Classification; Markers of proliferation; Pancreatic endocrine tumors; Prognosic

Indexed keywords

KI 67 ANTIGEN;

ARTICLE; CELL PROLIFERATION; ENDOCRINE TUMOR; HISTOPATHOLOGY; HUMAN; MITOSIS; PANCREAS ISLET CELL TUMOR; PANCREAS TUMOR; PROGNOSIS; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION;

ENDOCRINE GLAND NEOPLASMS; HUMANS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 0036813312     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Klöppel G, Heitz PU. Pancreatic endocrine tumors. Pathol Res Pract 1988; 183: 155-68.
2. Capella C, Heitz PU, Hötfler, Solcia E, Klöppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Archiv 1995; 425: 547-60.
3. Solcia E, Klöppel G, Sobin IH. Histological typing of endocrine tumours. World Health Organisation, International Classification of Tumours. Second Edition. Heidelberg, Springer, 2000.
4. Solcia E, Capella C, Klöppel G. Tumors of the pancreas. AFIP Atlas of Tumor Pathology, Third Series, Fascicle 20. Washington DC: Armed Forced Institute of Pathology, 1997.
5. Ordonez NG, Silva EG. Islet cell tumour with vacuolated lipid-rich cytoplasm: A new histological variant of islet cell tumour. Histopathology 1997; 31: 157-60.
6. Ligneau B, Lombard Bohas C, Partensky C, Valette PJ, Calender A, Dumortier J et al. Cystic endocrine tumors of the pancreas. Clinical, radiologic and histopathological features in 13 cases. Am J Surg Pathol 2001; 25: 752-60.
7. Cubilla AL, Hajdu SI. Islet cell carcinoma of the pancreas. Arch Pathol 1975; 99: 204-7.
8. Kenny BD, Sloan JM, Hamilton PW, Watt PC, Johnston CF, Buchanan KD. The role of morphometry in predicting prognosis in pancreatic islet cell tumors. Cancer 1989; 64: 460-5.
9. Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Fléjou JF et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 1998; 43: 422-7.
10. Stabile BE, Passaro E. Benign and malignant gastrinoma. Am J Surg 1984; 149: 144-9.
11. Zollinger RM. Gastrinoma: Factors influencing prognosis. Surgery 1984; 97: 49-54.
12. Ruszniewski P, Podevin P, Cadiot G, Marmuse JP, Mignon M, Vissuzaine C et al. Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type 1 multiple endocrine neoplasia. Pancreas 1993; 8: 295-304.
13. Weber HC, Venzon DJ, Lin JT, Fishbein VA, Orbuch M, Strader DB et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: A prospective long-term study. Gastroenterology 1995; 108: 1637-49.
14. Ellison EC. Forty-year appraisal of gastrinoma. Back to the future. Ann Surg 1995; 222: 511-21.
15. Vallot T, Mignon M, Lewin MJM, Bonfils S. Endocrinologie disgestive pratique. Bases cliniques et théoriques. 1996, John Libbey Eurotext, Paris.
16. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 1996; 429: 323-33.
17. Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: Treatment and prognosis. N Engl J Med 1987; 317: 1699-1701.
18. Donhuijsen K, Schmidt U, Hirche H, van Beuningen D, Budach V. Changes in mitotic rate and cell cycle fractions caused by delayed fixation. Hum Pathol 1990; 21: 709-14.
19. Guinebretière JM, Sabourin JC. Ki-67, marqueur de prolifération. Ann Pathol 1997; 17: 25-30.
20. Costes V, Marty-Ane C, Picot MC, Serre I, Pujol JL, Mary H, Baldet P. Typical and atypical bronchopulmonary carcinoid tumors: A clinicopathologic and KI-67-labeling study. Hum Pathol 1995; 26: 740-5.
21. Clarke MR, Weyant RJ, Watson CG, Carty SE. Prognostic markers in pheochromocytoma. Hum Pathol 1998; 29: 522-6.
22. Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: A comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996; 27: 1124-34.
23. Chaudhry A, Oberg K, Wilander E. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumour Biol 1992; 13: 27-35.
24. Gentil Perret A, Mosnier JF, Buono JP, Berthelot P, Chipponi J, Balique JG et al. The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. Am J Clin Pathol 1998; 109: 286-93.
25. Heymann MF, Joubert M, Nemeth J, Franc B, Visset J, Hamy A et al. Prognostic and immunohistochemical validation of the Capella classification of pancreatic neuroendocrine tumours: An analysis of 82 sporadic cases. Histopathology 2000; 36: 421-32.
26. Schindl M, Kaczirek K, Kaserer K, Niederle B. Is the new classification of neuroendocrine pancreatic tumors of clinical help? World J Surg 2000; 24: 1312-8.
27. Bordi C, Viale G. Analysis of cell proliferation and tumor antigens of prognostic significance in pancreatic endocrine tumors; in: Mignon M, Jensen RT (eds): Endocrine tumors of the pancreas, Front Gastrointest Res. Basel, Karger, 1995; 23: 45-59.
28. Padberg BC, Woenckhaus J, Hilger G, Beccu L, Jochum W, Range U et al. DNA cytophotometry and prognosis in typical and atypical bronchopulmonary carcinoids. A clinicomorphologic study of 100 neuroendocrine lung tumors. Am J Surg Pathol 1996; 20: 815-22.
29. Metz DC, Kuchnio M, Fraker DL, Venzon DJ, Jaffe G, Jensen RT et al. Flow cytometry and Zollinger-Ellison syndrome: Relationship to clinical course. Gastroenterology 1993; 105: 799-813.
30. Rigaud G, Missiaglia E, Moore PS, Zamboni G, Falconi M, Talamini G et al. High resolution allelotype of non-functional pancreatic endocrine tumors: Identification of two molecular subgroups with clinical implications. Cancer Res 2001; 6: 285-92.
31. Brambilla E, Negoescu A, Gazzeri S, Lantuejoul S, Moro D, Brambilla C et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996; 149: 1941-52.
32. Wang DG, Johnston CF, Buchanan KD. Oncogene expression in gastroenteropancreatic neuroendocrine tumors: Implications for pathogenesis. Cancer 1997; 80: 668-75.
33. Ebrahimi SA, Wang EH, Wu A, Schreck RR, Passaro E Jr, Sawicki MP. Deletion of chromosome I predicts prognosis in pancreatic endocrine tumors. Cancer Res 1999; 59: 311-5.
34. Chung DC, Brown SB, Graeme-Cook F, Tillotson LG, Warshaw AL, Jensen RT et al. Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. Cancer Res 1998; 58: 3706-11.
35. Barghorn A, Speel EJM, Farspour B, Saremaslani P, Schmid S, Perren A et al. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am J Pathol 2001; 158: 1903-11.
36. Bartsch D, Hahn SA, Danichevski KD, Ramaswamy A, Bastian D, Galehdari H et al. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene 1999; 18: 2367-71.
37. Srivastava A, Alexander J, Lomakin I, Dayal Y. Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumors. Hum Pathol 2001; 32: 1184-9.
38. Terris B, Scoazec JY, Rubbia L, Brégeaud L, Pepper MS, Ruszniewski P et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998; 32: 133-8.
39. Marion-Audibert AM, Nejjari M, Pourreyron C, Anderson W, Gouysse G, Jacquier MF et al. Effects of endocrine peptides on proliferation, migration and differentiation of human endothelial cells. Gastroenterol Clin Biol 2000; 24: 644-8.
40. LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 2001; 412: 877-84.
41. Kloppel G. Mixed exocrine-endocrine tumors of the pancreas. Semin Diagn Pathol 2000; 17: 104-8.
42. Regitnig P, Spuller E, Denk H. Insulinoma of the pancreas with insular-ductular differentiation in its liver metastasis - Indication of a common stem-cell origin of the exocrine and endocrine components. Virchows Arch 2001; 438: 624-8.
43. Majewski JT, Wilson SD. The MEN-1 syndrome: An all or none phenomenon? Surgery 1979; 86: 475-84.
44. Ballard HS, Frame B, Hartsock RJ. Familial multiple endocrine adenoma-peptic ulcer complex. Medicine 1964; 43: 481-516.
45. Heymann MF, Moreau A, Chetritt J, Murat A, Leborgne J, Le Neel JC et al. Etude anatomo-pathologique avec immunohistochimie de 61 tumeurs endocrines pancréatiques chez 16 patients atteints de néoplasie endocrinienne multiple de type 1 (NEM 1). Revue de la littérature. Ann Pathol 1996; 16: 167-73.
46. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM et al. Pancreatic involvement in von Hippel-Lindau disease. Gastroenterology 2000; 119: 1087-95.
47. Lubensky IA, Pack S, Ault D, Vortmeyer AO, Libutti SK, Choyke PL et al. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients. Histopathological and molecular genetic analysis. Am J Pathol 1998; 153: 223-31.
48. Terris B, Hammel P. Atteinte pancréatique au cours de la maladie de von Hippel-Lindau. Ann Pathol 2000; 20: 124-9.
49. Cadiot G, Mignon M, GRESZE, GENEM. Néoplasie endocrine multiple de type 1: aspects cliniques, implications pour la prise en charge des tumeurs endocrines duodéno-pancréatiques. Hepato-Castro 2000; 7: 365-72.
50. Cadiot G, Vuagnat A, Doukhan I, Murat A, Bonnaud G, Delemer B et al. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Gastroenterology 1999; 116: 286-93.